Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomes

Martin Jimenez, M.Gnant, M. I.Ejlertsen, B.Mansi, J. L.Ruiz-Borrego, M.Jakobsen, E. H.Osborne, C. K.Birhiray, R.Zhang, B.Wong, A.Moy, B.Holmes, F. A.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/27209enImpact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomesconference outputopen access10.1016/j.annonc.2020.03.0231569-8041http://www.annalsofoncology.org/article/S0923753420361020/pdf538879300074